

# PM566 Final Project Supplements

**Yating Zeng**

2022-12-08

Original Report PDF: **Report** [download]

Table 1: Supplementary table 1.Summary of Percent of people with at least one dose in females

Group	Min	Q1	Median	Q3	Max	Records
Female_Ages_<2yrs	0	3.73	5.30	6.27	7.1	122
Female_Ages_<5yrs	0	4.75	7.10	8.28	9.1	122
Female_Ages_02-04_yrs	0	5.43	8.20	9.57	10.5	122
Female_Ages_05-11_yrs	0	1.70	18.20	43.50	46.9	661
Female_Ages_12-17_yrs	0	37.40	75.15	84.80	86.6	676
Female_Ages_18-24_yrs	0	57.60	80.35	91.30	93.7	676
Female_Ages_25-39_yrs	0	60.60	80.25	88.70	90.5	676
Female_Ages_25-49_yrs	0	64.60	83.05	90.90	92.5	676
Female_Ages_40-49_yrs	0	71.50	87.90	94.70	95.0	676
Female_Ages_50-64_yrs	0	79.00	91.45	95.00	95.0	676
Female_Ages_65-74_yrs	0	90.10	95.00	95.00	95.0	676
Female_Ages_75+_yrs	0	83.80	91.25	95.00	95.0	676

Table 2: Supplementary table 2.Summary of Percent of people with at least one dose in males

Group	Min	Q1	Median	Q3	Max	Records
Male_Ages_<2yrs	0	3.70	5.20	6.20	7.0	122
Male_Ages_<5yrs	0	4.65	6.90	8.10	9.0	122
Male_Ages_02-04_yrs	0	5.25	8.05	9.38	10.2	122
Male_Ages_05-11_yrs	0	1.67	17.90	42.00	45.4	660
Male_Ages_12-17_yrs	0	33.98	70.35	79.60	81.3	676
Male_Ages_18-24_yrs	0	50.38	74.55	84.90	87.2	676
Male_Ages_25-39_yrs	0	55.48	75.15	83.30	85.0	676
Male_Ages_25-49_yrs	0	59.30	78.25	86.00	87.6	676
Male_Ages_40-49_yrs	0	66.30	83.75	91.00	92.3	676
Male_Ages_50-64_yrs	0	76.57	90.15	95.00	95.0	676
Male_Ages_65-74_yrs	0	91.10	95.00	95.00	95.0	676
Male_Ages_75+_yrs	0	87.70	95.00	95.00	95.0	676

Table 3: Supplementary table 3.Summary of Percent of people with at least one dose

Group	Min	Q1	Median	Q3	Max	Records
Sex_Female	0	59.1	75.0	84.2	86.6	676
Sex_Male	0	54.7	71.3	80.6	83.0	676

Table 4: Supplementary table 4.Summary of Percent of people completed a primary series

Group	Min	Q1	Median	Q3	Max	Records
Ages_<2yrs	0	0.70	1.40	2.10	2.8	99
Ages_<5yrs	0	0.40	2.00	3.20	4.4	116
Ages_02-04_yrs	0	0.72	2.50	3.98	5.4	114
Ages_05-11_yrs	0	1.40	11.25	36.10	39.2	630
Ages_12-17_yrs	0	20.95	64.20	73.20	74.7	667
Ages_18-24_yrs	0	43.20	67.85	74.90	76.6	676
Ages_25-39_yrs	0	48.58	69.05	74.70	75.9	676
Ages_25-49_yrs	0	52.27	72.15	77.50	78.6	676
Ages_40-49_yrs	0	58.77	77.55	82.40	83.4	676
Ages_50-64_yrs	0	67.90	82.45	87.00	88.6	676
Ages_65-74_yrs	0	80.20	89.85	94.10	95.0	676
Ages_75+_yrs	0	75.50	83.05	86.73	88.8	676

Table 5: Supplementary table 5.Summary of Percent of people completed a primary series in females

Group	Min	Q1	Median	Q3	Max	Records
Female_Ages_<2yrs	0	0.70	1.40	2.10	2.8	97
Female_Ages_<5yrs	0	0.90	2.20	3.35	4.5	107
Female_Ages_02-04_yrs	0	1.60	2.90	4.40	5.5	100
Female_Ages_05-11_yrs	0	1.50	11.80	36.70	39.9	629
Female_Ages_12-17_yrs	0	34.52	67.05	75.88	77.3	650
Female_Ages_18-24_yrs	0	46.68	70.75	77.90	79.6	676
Female_Ages_25-39_yrs	0	50.80	71.30	77.10	78.4	676
Female_Ages_25-49_yrs	0	54.58	74.25	79.70	80.9	676
Female_Ages_40-49_yrs	0	60.90	79.25	84.10	85.1	676
Female_Ages_50-64_yrs	0	68.80	82.75	87.30	88.9	676
Female_Ages_65-74_yrs	0	79.47	89.05	93.23	95.0	676
Female_Ages_75+_yrs	0	73.60	81.35	85.00	86.9	676

Table 6: Supplementary table 6.Summary of Percent of people completed a primary series in males

Group	Min	Q1	Median	Q3	Max	Records
Male_Ages_<2yrs	0	0.70	1.40	2.10	2.8	98
Male_Ages_<5yrs	0	0.52	2.00	3.18	4.3	114
Male_Ages_02-04_yrs	0	1.28	2.70	4.20	5.4	104
Male_Ages_05-11_yrs	0	1.40	15.10	35.50	38.5	615
Male_Ages_12-17_yrs	0	27.60	62.00	70.50	71.9	657
Male_Ages_18-24_yrs	0	39.58	64.65	71.60	73.2	676
Male_Ages_25-39_yrs	0	45.90	66.30	71.82	72.9	676
Male_Ages_25-49_yrs	0	49.50	69.45	74.70	75.8	676
Male_Ages_40-49_yrs	0	55.98	75.05	80.00	81.0	676
Male_Ages_50-64_yrs	0	66.30	81.40	86.00	87.6	676
Male_Ages_65-74_yrs	0	80.60	90.25	94.53	95.0	676
Male_Ages_75+_yrs	0	77.68	84.95	88.80	91.1	676

Table 7: Supplementary table 7.Summary of Percent of people completed a primary series


Group	Min	Q1	Median	Q3	Max	Records
Sex_Female	0	49.3	66.20	73.93	75.8	676
Sex_Male	0	45.1	62.55	70.30	72.1	676

## Supplementary tables


1. Summary tables tables for at least one dose
2. Summary tables for series dose

## Supplementary figures


1. Summary figures for one dose



Supplementary figure 8.Percent of people with at least one dose of females




Supplementary figure 9.Percent of people with at least one dose of males




Supplementary figure 10. Percent of people with at least one dose


## 2. Summary figures for series dose




Supplementary figure 11. Percent of people completed a primary series




Supplementary figure 12. Percent of people completed a primary series of males



Supplementary figure 13.Percent of people completed a primary series of males




Supplementary figure 14.Percent of people completed a primary series



Supplementary figure 15.Percent of people completed a primary seriee

## Visualization of the association


### 1. Visualization for one dose




Spplimentary figure 16.2020-2022 Percent of people with at least one dose




## 2. Visualization for series dose




Spplimentary figure 17.2020–2022 Percent of people completed a primary series



Spplimentary figure 18.2020–2022 Percent of people completed a primary series



Spplimentary figure 19.2020–2022 Percent of people completed a primary series of females



Spplimentary figure 20.Percent of people completed a primary series of males